Development of a Novel Platform for In Vivo Delivery of Antagomirs to Study Cetuximab Resistance in Colorectal Cancer
Abstract
The subject of the research is colorectal cancer treatment, and more specifically, overcoming epigenetic mechanisms of acquired cetuximab resistance in colorectal cancer. We have identified the epigenetic mechanisms that lead to cetuximab resistance in many patients, but the targets are microRNA molecules that are not able to be targeted by traditional drugs. The purpose of our research is to develop a novel delivery mechanism for so-called antagomirs, which could reverse cetuximab resistance. The scope of the proposed work will develop a novel delivery platform and to ultimately test in animal models cetuximab-resistant colorectal cancer to determine if it is efficacious. To date we have made significant progress on the synthesis of our antagomir delivery molecules, though that progress has been hampered in part by COVID-related absence from the laboratory.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2020
- Accession Number
- AD1108847
Entities
People
- Jacob Houghton
Organizations
- Vanderbilt University